Arcuro Medical Website
Arcuro Medical Receives FDA Regulatory Clearance (press release)
MISGAV, Israel, June 18, 2018 /PRNewswire/ -- Arcuro Medical Ltd. ("Arcuro"), a portfolio company of The Trendlines Group Ltd. ("Trendlines") (SGX: 42T) (OTCQX: TRNLY), announced today that it received regulatory clearance from the United States Food and Drug Administration (FDA) for its SuperBall™ meniscus repair system.
Meniscus tears are a common occurrence in many population groups: professional athletes, people who engage in daily sport activities, the ageing population, and people predisposed to cartilage problems.
To maintain knee functionality, current practice seeks to avoid removal of the meniscus, and prefers arthroscopic repair techniques. Shortcomings of current repair devices, however, include rigid implants, difficult-to-use delivery systems, and leave a knot in the joint space. These can cause poor repair quality, increased intraoperative failure, long-term damage to the meniscus, and device failures.
Arcuro has developed an all-suture meniscus repair system that preserves knee functionality and is secure, reliable, and effective. Arcuro completed an extensive and very suc...
